Quick Answer
PMV Pharmaceuticals, Inc. reported Net Income of -$77.74 million for fiscal year 2025.
PMV Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$77.74M -32.4% |
-$58.71M +14.9% |
-$68.96M +5.9% |
-$73.32M -26.7% |
-$57.85M -68.0% |
-$34.44M -35.8% |
| Diluted EPS | -$1.48 -29.8% |
-$1.14 +20.8% |
-$1.44 +10.6% |
-$1.61 -25.8% |
-$1.28 +46.7% |
-$2.40 |
| Total Assets | $116.56M -39.1% |
$191.29M -24.1% |
$252.15M -6.7% |
$270.31M -18.5% |
$331.57M -9.3% |
$365.53M +254.8% |
| Cash and Equivalents | $37.98M -7.1% |
$40.88M +8.4% |
$37.71M -65.2% |
$108.30M -37.2% |
$172.47M -52.3% |
$361.42M +393.2% |
| Stockholders Equity | $104.71M -40.5% |
$176.08M -22.0% |
$225.69M -8.3% |
$246.03M -20.3% |
$308.56M -14.1% |
$359.12M +609.6% |
| R&D Expense | $69.88M +19.4% |
$58.53M +4.7% |
$55.88M +7.5% |
$51.99M +42.5% |
$36.49M +52.5% |
$23.93M +15.3% |
| Operating Income | -$86.21M -0.9% |
-$85.45M -6.6% |
-$80.13M -4.0% |
-$77.04M -32.2% |
-$58.29M -66.8% |
-$34.94M -31.2% |
| Shares Outstanding | 53.33M +2.7% |
51.94M +1.0% |
51.45M +12.4% |
45.77M +0.7% |
45.43M +1.5% |
44.78M +1370.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$21.06M | -9.5% | +0.7% |
| Diluted EPS | September 30, 2025 | -$0.40 | -8.1% | +2.4% |
| Total Assets | September 30, 2025 | $133.84M | -40.1% | -12.4% |
| Cash and Equivalents | September 30, 2025 | $36.34M | -25.6% | -17.7% |
| Stockholders Equity | September 30, 2025 | $121.00M | -38.9% | -13.9% |
| R&D Expense | September 30, 2025 | $18.21M | +7.5% | -1.0% |
| Operating Income | September 30, 2025 | -$22.52M | -2.9% | +1.6% |
| Shares Outstanding | September 30, 2025 | 52.99M | +2.4% | +0.0% |
- PMV Pharmaceuticals, Inc. reported Net Income of -$77.74 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -32.4% in Net Income compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Diluted EPS of $1.48 per share (loss) for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -29.8% in Diluted EPS compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Total Assets of $116.56 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -39.1% in Total Assets compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Cash and Equivalents of $37.98 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -7.1% in Cash and Equivalents compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Stockholders Equity of $104.71 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -40.5% in Stockholders Equity compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported R&D Expense of $69.88 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed an increase of +19.4% in R&D Expense compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Operating Income of -$86.21 million for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed a decrease of -0.9% in Operating Income compared to the prior fiscal year.
- PMV Pharmaceuticals, Inc. reported Shares Outstanding of 53.33 million shares for fiscal year 2025.
- PMV Pharmaceuticals, Inc. showed an increase of +2.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: